Cogent Biosciences (COGT) Share-based Compensation (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Share-based Compensation data on file, last reported at $16.9 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 68.94% year-over-year to $16.9 million in Q1 2026; TTM through Mar 2026 was $38.3 million, a 6132.2% increase from a year earlier, with the FY2025 full-year figure at $46.1 million, up 338.85% from the prior year.
• Share-based Compensation for Q1 2026 stood at $16.9 million, up from $1.1 million in the prior quarter.
• Over the last five years, Share-based Compensation for COGT reached as high as $16.9 million in Q1 2026 and fell as low as -$29.8 million in Q4 2024.
• Historically, Share-based Compensation has averaged $5.4 million across 5 years, with a median of $8.8 million in 2023.
• On a YoY basis, Share-based Compensation climbed as much as 3031.0% in 2024 and fell as far as 436.27% in 2024.
• Year by year, Share-based Compensation stood at $5.0 million in 2022, then jumped by 75.72% to $8.9 million in 2023, then sank by 436.27% to -$29.8 million in 2024, then soared by 103.7% to $1.1 million in 2025, then jumped by 1437.09% to $16.9 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $16.9 million in Q1 2026, $1.1 million in Q4 2025, and $10.6 million in Q3 2025.